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Abstract 24 
 25 
Dogma for reasons of immune privilege including sequestration (sic) of ocular 26 
antigen, lack of lymphatic and immune competent cells in the vital tissues of the 27 
eye has long evaporated. Maintaining tissue and cellular health to preserve 28 
vision requires active immune responses to prevent damage and respond to 29 
danger. A priori the eye must contain immune competent cells, undergo immune 30 
surveillance to ensure homeostasis as well as an ability to promote 31 
inflammation. By interrogating immune responses in non-infectious uveitis and 32 
compare with age-related macular degeneration (AMD), new concepts of 33 
intraocular immune health emerge. The role of macrophage polarisation in the 34 
two disorders is a tractable start. TNF–alpha regulation of macrophage 35 
responses in uveitis plays a pivotal role, supported via experimental evidence 36 
and validated by recent trial data. Contrast this with the slow; insidious 37 
degeneration in atrophic AMD or in neovasular AMD, with the compelling genetic 38 
association with innate immunity and complement, highlights an ability to 39 
attenuate pathogenic immune responses and despite known inflammasome 40 
activation.  Yolk sac derived microglia maintain tissue immune health. The result 41 
of immune cell activation is environmentally dependent, for example on retinal 42 
cell bioenergetics status, autophagy and oxidative stress, alterations in which 43 
skew interaction between macrophages and retinal pigment epithelium (RPE). 44 
For example, dead RPE eliciting macrophage VEGF secretion but exogenous IL-4 45 
liberates an anti-angiogenic macrophage sFLT-1 response. Impaired autophagy 46 
or oxidative stress drives inflammasome activation, increases cytotoxicity and 47 
accentuation of neovascular responses, yet exogenous inflammasome derived 48 
cytokines such as IL-18 and IL-33 attenuate responses.  49 
 50 
 51 
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 53 
  54 
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Introduction 55 
 56 
Keeping the peace. 57 
 58 
To maintain the viability of both a clear media and a functional neuroretina and 59 
vision requires an ability to maintain cellular health under stress and to various 60 
extents require an orchestration of an immune response (1-3).  61 
 62 
The eye and in particular the retina and the choroid, is furnished with a 63 
contiguous network of myeloid cells – namely microglia and macrophages (4, 5). 64 
These cells alongside the ascribed non-immune cells (such as RPE and Muller 65 
Glia in the retina) establish an immune tissue tone that maintains homeostasis. 66 
Myeloid cell activation in the retina is regulated by a tonic break functioning to 67 
prevent overt activation but maintain a scavenger function for daily 68 
housekeeping. The argument as to whether microglia contribute to onset of 69 
ocular inflammation (6)is balanced against their homeostatic role in maintaining 70 
a healthy retina, and where data is supportive (2). Microglia from a network 71 
throughout the retina, and display regulatory phenotypes and functions 72 
consistent with other tissue-resident macrophages elsewhere in the body (4). 73 
Furthermore, although we are still awaiting the advent of live in vivo imaging of 74 
immune cell trafficking to understand the dynamics and kinetics of cell 75 
trafficking and/or turnover, the results experimentally demonstrate a 76 
persistence of macrophages throughout disease (7, 8) and where myeloid, 77 
macrophage, and T cell accumulations are noted in later disease (9). The activity 78 
and extent of immune surveillance and cell traffic is yet to be determined in man.  79 
 80 
So one paradigm is that the retina possesses an activation threshold to subvert 81 
damage. One example of a tonic break that supports homeostasis is the 82 
regulation of macrophage activation via the cognate-receptor interplay of 83 
CD200R and its ligand, CD200. CD200 is ubiquitously expressed on macrophages, 84 
neurons and endothelium (10-13) and perturbing their interaction results in an 85 
aggressive disease phenotype (14, 15). If we attempt to reconstitute and de-86 
activate macrophage function (by direct ligation of CD200R with anti-CD200R 87 
monoclonal antibodies or by a CD200Fc), attenuation of retinal or CNS 88 
inflammation can be achieved (14, 16) as well as regulation of other myeloid 89 
cells including mast cells in the lung (17-20). 90 
 91 
How do we keep the peace? A premise lies that there is continual 92 
immunosurveillance, akin to CNS, and that alongside the immune cell inhabitants 93 
of the retina and choroid, together achieve constant sensing to respond to danger 94 
signals. In support, we observe that tissue damage in experimental retinal 95 
inflammation is significantly attenuated when macrophages are removed (21, 96 
22)or macrophage/monocyte activation is blocked (16, 23-25). Experimentally, 97 
we observe that the tissue is protected when TNF-alpha activity is neutralised 98 
(and indeed show the requisite requirement of TNF for macrophage activation in 99 
ocular inflammation (26-28)), or by reprogramming macrophage activation 100 
threshold with CD200R treatment. These consistent observations have led to a 101 
pipeline for therapeutic opportunities to redress activation thresholds of 102 
immune cells.  103 
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A tail of two conditions 104 
 105 
Understanding Uveitis. 106 
 107 
Uveitis is defined as an “orphan disease”, yet in 2010 uveitis accounted for 10% 108 
of the estimates of 285 million people visually impaired and 39 million blind 109 
(29). Non-infectious uveitis comprises a heterogeneous group of disorders 110 
diagnosed based on their clinical characteristics and whether associated with 111 
systemic disorders (30, 31).  112 
 113 
The healthcare burden is significant, where non-infectious uveitis accounts for 114 
substantial medical, social and workload costs in the USA and aligns with data 115 
that persistent disease gives rise to considerable ocular and systemic morbidity 116 
(24, 32-34). 117 
 118 
The clinical phenotype of non-infectious intraocular inflammation is replicated in 119 
experimental animal models that are driven by immune responses to self-120 
antigen (35). The animal models, such as experimental autoimmune 121 
uveoretinitis (EAU) support a role for autoimmunity with clinical-pathological 122 
features bearing remarkable similarity to man (7, 8, 36, 37).  The currently held 123 
notion is that of a CD4+ T helper cell-driven process and supported in man by the 124 
association of sympathetic ophthalmia and Vogt–Koyanagi–Harada disease with 125 
specific HLA class II alleles as well as the identification of ocular antigen-126 
responsive T cells in both the peripheral blood and eyes of patients (38-40).  127 
When T cells are activated they assume different functional phenotypes directed 128 
through canonical transcription factors (41, 42) and characterised by the 129 
secretion of signature cytokines (43, 44). In EAU, both Th1 and Th17 T helper 130 
cells are important inducers of autoimmune disease [(35, 45)]. It is the cytokines 131 
(especially IFN-γ produced by Th1 cells) produced by these cells that activate the 132 
non-specific mononuclear tissue infiltration (principally macrophages) and 133 
recruit neutrophils as seen in EAU (e.g., through IL-17 produced from Th17 cells; 134 
(7, 8, 23, 24, 26-28)).  135 
 136 
However, some of the uveitic conditions are likely to be driven through both 137 
autoinflammatory and autoimmune disease processes. Advances defining the 138 
molecular pathology of autoinflammatory conditions have illuminated how many 139 
inflammatory diseases are driven by genetic mutations affecting elements of the 140 
innate immune system (46). For example, in Blau syndrome, there is a gain-of-141 
function mutations in the NOD2 gene driving nuclear factor κB (NFκB) 142 
transcriptional activation (47) and gives rise to early onset inflammatory disease 143 
and in the skin there is an abundance of CD4+ T cells, CD68+ macrophages and 144 
extensive expression of IFN-γ, IL-17, and IL-6 (48). Uveitic conditions express 145 
changes in inflammasome activation, including Behcet’s and 146 
spondyloarthropathies. Also the complex interplay between changes in innate 147 
immunity, autoinflammation and autoimmunity implicates an infectious aetio-148 
pathogenesis. The inflammasome is a multiprotein complex comprising a sensor 149 
protein, the adaptor protein ASC (apoptosis-associated speck-like domain 150 
containing caspase recruitment domain), and the inflammatory protease 151 
caspase-1. The eye has many inflammasome-forming sensors (49), including 152 
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NLRP receptor molecules (nucleotide binding domain and leucine-rich repeat 153 
containing pyrin domain family). Inflammasome-dependent biological effects 154 
may be mediated not only by IL-1b and IL-18, but also by the multifaceted 155 
activities of caspase-1. Secondary effects of protecting against inflammasome 156 
activation, such as when autophagy is increased is observed and has relevance to 157 
degenerative disease or remodeling during persistent inflammatory diseases, 158 
such as uveitis (50, 51). The implications of which will be discussed later. It is 159 
clear, however that uveitis we observe as a result of autoimmune responses or 160 
through activation of cellular pathways linked to autoinflammatory disorders, 161 
namely activation of inflammasome, is an appropriate response to the signals 162 
received. That is, it is a sequel to an overwhelming adaptive T cell or innate 163 
PAMP-derived response to danger signals. This results in further recruitment of 164 
immune cells to the target tissue and these cells inflict the subsequent damage 165 
we observe clinically. However, control of responses of both innate and adaptive 166 
immunity are likely more intertwined. Adaptive responses and T cell 167 
polarization rely on both close interplay between intracellular complement 168 
regulation and NLRP3 assembly (52). 169 
 170 
The knowledge accrued from animal models of uveitis and in particular how to 171 
subvert tissue damage, has illuminated pivotal role for many targets.  The most 172 
successful to date is TNF-alpha (1, 53). Controlling the macrophage response is a 173 
principal effect of anti-TNF-a agents. The ability of macrophages to respond to 174 
environmental, cytokine, and receptor signals provides adaptability in 175 
controlling inflammation and in restoring structure and function (54). 176 
Translation will remain challenging (given the plasticity of myeloid cells and how 177 
rapidly they adapt) when considering timing of treatment. In EAU there are 178 
other compounding influences to consider for therapy and in particular whether 179 
such mechanisms exist for translation for AMD therapeutics. For example, 180 
complement is activated during disease; whilst arguably not critical to 181 
development of inflammation and suppressing or regulating complement 182 
diminishes EAU expression (55-57). A convergant mechanism of action is at the 183 
level of suppressing macrophage activation. Similarly, chemokine gradient 184 
support or perturbation can suppress or exacerbate EAU disease, where the 185 
myeloid compartments are being manipulated (58-62). 186 
 187 
For targeting TNF-alpha, we now have substantial evidence through randomised 188 
clinical trials exhibiting successful outcomes. The Abbvie sponsored VISUAL 189 
trials in adults have shown adalimumab (a humanized anti-TNFalpha 190 
monoclonal antibody) significantly lowered the risk for uveitic flare or vision 191 
loss in patients with non-infectious, intermediate, posterior or panuveitis upon 192 
complete prednisone taper in both active (uncontrolled despite 10-60 mg 193 
prednisone, VISUAL I) and inactive (corticosteroid-dependent on ≥10 mg 194 
prednisone, VISUAL II) uveitis. The enpoints were statistically significant in 195 
favour of adamimumab reducing the time to treatment failure (HR= 196 
 0.56 (0.40-0.76, P<0.001) for VISUAL I and HR=0.52 (0.37-0.74, P<0.001) for 197 
VISUAL II)(63). The safety profile was consistent with the known safety profile 198 
across the approved ADA indications and the patient population. In children, the 199 
SYCAMORE randomised placebo-controlled trial looking at effectivity and safety 200 
of adalimumab therapy in methrotrexate-resistent JIA-Uveitis provides evidence 201 
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of efficacy of adalimumab treatment used in addition to methotrexate. The final 202 
analysis of the primary outcome of time to treatment failure was showed a 203 
positive treatment effect in favour of adalimumab: hazard ratio (HR) 0.27 (95% 204 
CI 0.13-0.52); p<0.0001 (64).  205 
  206 
 207 
Age-related macular degeneration (AMD) and altered immunity 208 
 209 
AMD, as the leading cause of central visual loss affects the choriocapillaris, 210 
Bruch’s membrane and the retinal pigment epithelium, with dysfunction and 211 
death of overlying photoreceptors.  If we compare patients with ocular 212 
inflammatory disorders such as a uveitis that show alterations in the circulating 213 
immune system with AMD, we observe similar. Complement and innate immune 214 
gene polymorphisms have been clearly implicated in the development of AMD 215 
(65-67). While differences in complement regulation between those with the 216 
variant and the wild type alleles have been reported as well as the impact of rare 217 
variants in the rapidity of disease onset (68), functional immune mechanism 218 
remain elusive, particularly with respect to CFH. We have shown that CFH binds 219 
mCRP to dampen its proinflammatory activity. CFH from AMD patients carrying 220 
the "risk" His402 polymorphism display impaired binding to mCRP, and 221 
therefore proinflammatory effects of mCRP remain unrestrained, at least in vitro 222 
(69). Whether this translates to disease or not requires validation but even so 223 
alone does not account for all the immune related changes we observe in AMD. 224 
 225 
It is clear immune dysregulation exists and data continues to further illuminate 226 
the original notion (70). Drusen are immunologically active deposits containing 227 
oxidative lipids, lipofuscin, complement and other immune activating 228 
components that develop as the consequence of RPE stress and altered tissue 229 
homeostasis(70, 71). Degenerating RPE is also a major source for drusen 230 
components, indicating that age-related changes in RPE may be a causal factor 231 
and drive disease progession as we will discuss further(72).  For example, cells 232 
from eyes with AMD exhibit upregulated expression of immune receptors and 233 
molecules (73, 74), including expression of IL-17RC, a receptor for a dimer of IL-234 
17A and IL-17F and activation of NLRP-3 inflammasome that promotes cleavage 235 
of pro-IL-1beta and IL-18 (75-77).  Furthermore, both macrophages and 236 
multinucleated giant cells, mainly associated with vascular channels and breaks 237 
in Bruch’s membrane are evident (78-83). Macrophage subtype changes have 238 
been noted in the eyes of patients with AMD, including a change in the M1/M2 239 
ratio in AMD eyes compared to that in control eyes of the same age (83). With all 240 
the data demonstrating immune activation we need to reconcile these findings 241 
with the knowledge that the development of AMD is slow. Firstly, given that AMD 242 
is insidious, altered immune responses within the tissue likely occur as a result 243 
of persistent lifetime oxidative stress and changes to cell health in the retina.  In 244 
such conditions, a concept of para-inflammation emerges (3, 84), where evidence 245 
of activated immunity (complement, antibody deposition, macrophage and 246 
microglia activation) serves to protect the tissue and prevent overt inflammation 247 
and tissue destruction. Does this demonstrate the success of active immune 248 
regulation in the eye? Secondly, the inflection to a more rapid progression (if 249 
indeed that occurs) may be co-incident to the heightened inflammasome 250 
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activation. The consequence is a switch to a more ‘classical’ chronic 251 
inflammatory responses propagating tissue destruction and angiogenesis and as 252 
‘frame-shots’ of evidence in man supports (3, 85-87). The cause of change from 253 
para-inflammation to chronic inflammation remains unknown. We can however 254 
make in roads and unwrap possible mechanisms for AMD by comparing with 255 
immune mediated uveitis and the role of innate immunity and in particular 256 
macrophages. 257 
 258 
 259 
The altered faces of Macrophage activation  260 
 261 
Persistent ‘inflammation’, altered immunosurveillance and aberrant healing 262 
responses?  263 
 264 
Increasing evidence suggests there is persistent dysregulation of 265 
immunosurveillance of the retina following the induction of disease (7, 9, 37). If 266 
we take the notion that para-inflammation or any evidence of immune responses 267 
reflects active immune regulation, then it is possible that following the original 268 
insult or danger signal in inflammatory disease the tissue modifies or heightens 269 
immunosurveillance. The result may be predicted (not exclusively) to result in: 270 
(i) persistence of inflammatory cells and continued immune targeted 271 
destruction; (ii) persistent tissue remodelling and thus potential altered function 272 
as a result of for example, aberrant wound healing, and (iii) maintained 273 
architecture but residual increased numbers of inflammatory cells as a 274 
consequence of heightened thresholds (both activation threshold (see above) as 275 
well as ‘patrolling’ cell numbers) to maintain tissue integrity and health.   276 
 277 
Talking this further and in support of points (ii) and (iii) above, a principal 278 
observation in inflammatory disease such as murine EAU is the persistence of 279 
inflammation, implying that the threshold of myeloid activation is not reset. It is 280 
in this context that para-inflammation’ is operative or as said above, another way 281 
of describing this phenomenon are immune responses to protect tissue – 282 
heightened immunosurveillance with or without tissue remodelling. In the 283 
presence of persistent T cell responses, the tissue remains vulnerable. A constant 284 
macrophage infiltrate remains, although in nearly all models the macrophages 285 
exhibit an alternative activation phenotype in later stages (as opposed to the 286 
early disease classical activation phenotype) and this again supports concept of 287 
tissue remodelling. Taken together, a consequence of a chronic immune cell 288 
infiltrate is persistent tissue remodelling contemporaneous with 289 
macrophage/monocyte activation, of which one hallmark result is angiogenesis. 290 
The angiogenic response during persistent tissue immune, cell infiltrate requires 291 
an operative CCL2-CCR2 axis, but is also influenced by multifunctional matrix 292 
proteins, such as thrombospondin-1 (TSP-1) (9).  Subverting the angiogenic 293 
response (but without altering the initial inflammation and antigen-specific 294 
targeting of tissue) by knocking out matricellular proteins such as TSP-1 results 295 
as expected persistent disease (as observed in wild-type mice (88)) but notably 296 
results in increased angiogenesis (a detriment to retinal function as observed in 297 
neovascular diseases AMD). The results infer that there is matricellular control 298 
(e.g.TSP) of macrophage activation in terms of remodelling and angiogenesis 299 
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during T cell mediated responses and whilst initial disease severity is not altered 300 
with loss of TSP, regulating tissue remodelling, (as determined by extent of 301 
angiogenesis) is perturbed.  302 
  303 
 304 
 305 
Macrophage conditioning, angiogenesis and tissue viability. 306 
 307 
 308 
As introduced above, the function and phenotype of macrophage subtypes is 309 
conditioned by signals encountered within the tissue microenvironment.  The 310 
paradigm of M1 and M2 macrophages has been studied with respect to 311 
angiogenesis (89-92). Classical activation generates M1 macrophages, which 312 
have pro-inflammatory functions as we have discussed, operative during 313 
inflammation in EAU and impart tissue destruction that is effectively neutralized 314 
via blocking TNF-alpha activity. Alternatively activated M2 macrophages confer 315 
responses related to wound healing, and are capable of generating VEGF and 316 
promoting angiogenesis. However, pathological angiogenesis is observed most 317 
commonly in the presence of M2 macrophages (93). The role of macrophages in 318 
driving a VEGF-dependent angiogenic response remains debatable. Data 319 
supported by recent evidence from studies using the laser-induced CNV model 320 
show that early initiation of choroidal angiogenesis is dependent upon 321 
macrophage phagocytosis of damaged RPE components. This in turn elicits an 322 
Arg-1+, VEGF+ M2 phenotype that is only seen early in the genesis of the 323 
angiogenic bed (94). Contrary, in an attempt to understand VEGF and upstream 324 
players using the mouse CNV models with various conditional inactivation of 325 
Vegfa, Hif1a, or Epas1, macrophages were not the source of VEGF (95).  326 
 327 
But yet on the other hand, macrophage subtypes are plastic, and functional 328 
outcomes may not be straightforward. For example, IFN- and TLR4 ligation 329 
(with LPS) can generate VEGF+ M1 macrophages, but PGE2 remains a potent 330 
stimulus for the generation VEGF+ M2 macrophages as well, in vitro. So when 331 
macrophages are alternatively activated via IL-4 they result in a sFlt-1-secreting 332 
M2 cell and this is seen in both mouse and man (96). In man, macrophages 333 
associated with CNV or in specimens of AMD retina that are assessed using 334 
immunohistochemistry confirm the nature of VEGF-expressing CD68+ cells (97). 335 
Finally, perturbing macrophage function can attenuate neovascularization in 336 
experimental models (98). 337 
 338 
What causes an inflection in immune responses that may drive conversion from 339 
early AMD to late stage of AMD?  One switch as we discussed above is that of the 340 
change from a homeostatic para-inflammatory response, which may become 341 
increasingly operative with age, to an unchecked persistent low grade 342 
inflammatory response resulting in loss of RPE and/or pathological 343 
angiogenesis(3). We have recently demonstrated that RPE destruction in the 344 
model of laser-induced CNV polarizes infiltrating myeloid cells toward a pro-345 
angiogenic phenotype.  The latter can be perturbed through the augmentation of 346 
inhibitory CD200R signaling or through the administration of Th2 cytokines to 347 
either tonically suppress macrophage activation or drive anti-angiogenic 348 
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function respectively(94, 96, 98).  Thus our data and those from others(99, 100) 349 
support the concept that interplay between macrophage and RPE within the 350 
subretinal space likely contributes to disease progression. 351 
 352 
Autophagy is the central cellular housekeeping function that facilitates the 353 
disposal of long-lived, defective organelles (eg. mitochondria) and protein 354 
aggregates through “self-eating” via autophagosomes and lysosomes(101). 355 
Increasing evidence indicates impaired autophagy is associated with age-related 356 
degenerative disorders, highlighted by studies in which pharmacological or 357 
genetic manipulation of autophagy pathways can induce cellular and tissue 358 
degeneration in vitro and in vivo(102-104). In the eye, autophagy is highly active 359 
in RPE and photoreceptor cells, and impaired autophagy in RPE leads to RPE 360 
transcytosis and exocytosis and early signs of RPE degeneration(104-106). 361 
Impaired autophagy generates dysfunctional RPE that modulates macrophage 362 
responses, driving further cell death and promotes angiogenesis in the eye(107). 363 
There is therefore a growing body of evidence to support interaction between 364 
RPE degeneration and subsequent macrophage activation that may simulate 365 
earlier events occurring in AMD leading to progression of disease and 366 
neovascularisation.  367 
 368 
Moreover, the activation of the NLRP3 inflammasome (that is almost certainly a 369 
protective response initially), provides a rapid response to danger in order to 370 
preserve tissue function and integrity. The corollary is that inflammasome 371 
activation may also cause tissue damage. NLRP3-inflammasome can 'sense' 372 
drusen isolated from human AMD donor eyes that liberates active IL-1β and 373 
Interleukin (IL)-18 production. IL-18 however has been shown to protect against 374 
the development of choroidal neovascularization (108).  Another family member, 375 
and in a similar vain is IL-33. IL-33 is unique as it is active without caspase-1 376 
cleavage and does not require inflammasome activation for secretion and 377 
bioactivity (109).  IL-33 triggers an inflammatory response, recruiting 378 
monocytes, contributing to photoreceptor loss in a photoxic retinal model of 379 
degeneration (110) and infers a pathogenic role of endogenous IL-33 and an a 380 
priori for neutralizing IL-33 to reduce myeloid cell accumulation as a possible 381 
intervention. However, as with IL-18, and in consideration of the emerging role 382 
of IL-33 in inflammatory disorders (111, 112) and in the absence of progressive 383 
cell death, IL-33 regulates tissue responses. IL-33 subverts angiogenesis, via 384 
direct inhibition of fibroblasts and endothelial cells that express high levels of 385 
ST2, and recombinant IL-33 protects against CNV development (113).  386 
 387 
 388 
Ageing, Senescence and bioenergetic sources 389 
 390 
O’Neill highlighted the prominence to the ‘Warburg effect’ in context to immune 391 
responses and the role in the pathogenesis of immune mediated disorders, such 392 
as diabetes and atherosclerosis (114-116). Extrapolating from Warburg’s 393 
original observations that tumour cells undergo a bioenergetic switch 394 
(permissive for survival and proliferation), to aerobic glycolysis, we now 395 
appreciate that such bioenergetic switch occurs in the ageing and early AMD 396 
RPE. The Warburg effect rapidly provides ATP and enhances metabolic pathways 397 
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to support immune cell function. With age, there is increasing strain on 398 
mitochondrial function, autophagy and mitophagy to maintain cellular and tissue 399 
health. A response for the good is to divert energy sources – Warburg effect - to 400 
maintain function against the stress, allow an ability to proliferate if required, 401 
and respond to the oxygen drain by upregulating transcription factor HIF-1.  402 
However, with that also comes a price; inflammasome activation. 403 
 404 
Any cell with mitotic potential may undergo senescence (often associated with 405 
ageing), resulting in cell cycle arrest but also a cell with a high metabolic demand 406 
and with respect to inflammation a distinct secretory phenotype that promotes 407 
inflammation (117). The senescent associated secretory phenotype provokes 408 
further immune mediated deleterious effects on the local tissue 409 
microenvironment.  Senescence also evokes an anti-Warburg effect. All told, 410 
senescence may be a drive of immune-mediated degenerative disorders, such as 411 
AMD. 412 
 413 
In degenerative disease the Warburg effect may be beneficial. The upregulation 414 
of the inflammasome may act to protect cells and subvert angiogenesis as shown 415 
with IL-18 and IL-33. Such a response, and where we observe inflammation is 416 
one of the constituents of the para-inflammatory response we discussed earlier. 417 
Parainflammation works to enable and reset immune thresholds to protect the 418 
tissue.  419 
 420 
The Immune response work group at the annual Beckman Initiative for Macular 421 
Research conference concluded in 2014 with a provocation and notion that AMD 422 
is an inflammatory disease, more permissive with age due to an interaction of an 423 
aged systemic immune system with an aged or senescent eye. Immune activation 424 
that protects and any dysegulation that promotes damage is orchestrated 425 
through a playlist of many of the same players, and not exhaustively, altered 426 
intracellular lipid handling, Warburg effect, inflammasome activation and 427 
macrophage activation. However, as discussed here, the outcome is dependent 428 
on other interactions and external forces, such as the many associations we 429 
appreciate with complement protein polymorphisms that will dictate altered cell 430 
responses as well as the insidious and persistent influence of oxidative stress 431 
and senescence.  432 
 433 
 434 
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